Literature DB >> 27072927

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

J Naidoo, D B Page, B T Li, L C Connell, K Schindler, M E Lacouture, M A Postow, J D Wolchok.   

Abstract

Entities:  

Year:  2016        PMID： 27072927      PMCID： PMC5006114          DOI： 10.1093/annonc/mdw141

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  41 in total

1.  Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection.

Authors:  Gurhan Sisman; Erol Barbur; Didem Saka; Sibel Erdamar Cetin
Journal:  Cancer Immunol Immunother       Date:  2021-01-22       Impact factor: 6.968

2.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

Review 3.  Biological agents in gastrointestinal cancers: adverse effects and their management.

Authors:  Nivedita Arora; Arjun Gupta; Preet Paul Singh
Journal:  J Gastrointest Oncol       Date:  2017-06

4.  Hypothalamic expression of PD-L1: does it mediate hypothalamitis?

Authors:  Erika Iervasi; Antonella Strangio; Daniele Saverino
Journal:  Cell Mol Immunol       Date:  2019-04-12       Impact factor: 11.530

Review 5.  Targeting the programmed death-1 pathway in lymphoid neoplasms.

Authors:  Chi Young Ok; Ken H Young
Journal:  Cancer Treat Rev       Date:  2017-02-11       Impact factor: 12.111

Review 6.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 7.  Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.

Authors:  Naziheh Assarzadegan; Elizabeth Montgomery; Robert A Anders
Journal:  Virchows Arch       Date:  2017-11-15       Impact factor: 4.064

8.  Immune Checkpoint Inhibitor-Associated Pericarditis.

Authors:  Mehmet Altan; Maria I Toki; Scott N Gettinger; Daniel E Carvajal-Hausdorf; Jon Zugazagoitia; John H Sinard; Roy S Herbst; David L Rimm
Journal:  J Thorac Oncol       Date:  2019-03-07       Impact factor: 15.609

9.  Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.

Authors:  Hye In Kim; Mijin Kim; Se-Hoon Lee; So Young Park; Young Nam Kim; Hosu Kim; Min Ji Jeon; Tae Yong Kim; Sun Wook Kim; Won Bae Kim; Sang-We Kim; Dae Ho Lee; Keunchil Park; Myung-Ju Ahn; Jae Hoon Chung; Young Kee Shong; Won Gu Kim; Tae Hyuk Kim
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

10.  Immune Checkpoint Inhibitor-Associated Myocarditis.

Authors:  Sarju Ganatra; Tomas G Neilan
Journal:  Oncologist       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.